Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Hepatitis Virus Vaccine Immune Therapy"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 3749
Special Issue Editor
Interests: vaccine; hepatitis virus vaccine
Special Issue Information
Hepatitis viruses mainly include four major viruses (Hepatitis virus A, B, C, and E), although there are some other viruses that are capable of inducing hepatitis in humans. These viruses are hepatotropic in nature and can induce various types of liver disease. There have been significant insights into the epidemiology, virology, pathogenesis, prevention and management of patients infected with hepatitis viruses. However, a considerable number of new infections of all four hepatitis viruses still occur each year. In addition, several million patients are chronically infected with hepatitis B virus (HBV) and hepatitis C virus (HCV). Thus, more insights should be developed into all aspects of these viruses to meet the WHO target of ‘Elimination of Hepatitis by 2030’. A prophylactic vaccine should be developed for HCV. HBV is a non-cytopathic virus and host immunity seems to play a significant role in the pathogenesis of HBV-induced liver diseases. In this context, more insights are required regarding virus–host interactions (immunity). These understandings may provide fundamental evidence for the development of new modes of immune therapies. The aim of this Special Issue is to provide a platform for the development of greater understanding of hepatitis viruses, their interplay with the immune system, and new and innovative therapies from all disciplines.
Dr. Sheikh Mohammad Fazle Akba
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatitis virus
- hepatitis B virus
- hepatitis C virus
- immune therapy